. | . |
China embarks on clinical trial for virus vaccine by Staff Writers Beijing (AFP) March 22, 2020
China has started the first phase of a clinical trial for a novel coronavirus vaccine, records show, as the world's scientists race to find a way to combat the deadly pathogen. It comes after US health officials said last week they had started a trial to evaluate a possible vaccine in Seattle. The Chinese effort began on March 16 -- the same day as the US announcement -- and is expected to continue until the end of the year, according to a filing in the country's Clinical Trial Registry, dated March 17. "Volunteers of the COVID-19 phase one trial have already started receiving the vaccine," a staff member involved in the government-funded project told AFP on Sunday. The 108 participants, aged between 18 and 60, will be tested in three groups and given different dosages. They are all residents of the central city of Wuhan -- where the new coronavirus first emerged late last year. As the COVID-19 pandemic rages and governments step up protection measures, pharmaceutical companies and research labs around the world are working at full tilt. There are currently no approved vaccines or medication for the new disease, which has killed more than 13,000 people worldwide so far. The vaccine trial announcements come amid an escalating feud between the US and China over the pandemic, with President Donald Trump enraging Beijing by speaking of the "Chinese virus". China's nationalistic Global Times published an opinion piece last week noting "the development of a vaccine is a battle that China cannot afford to lose". But the quest is expected to take time -- the US candidate vaccine may take another year to 18 months before becoming available. An antiviral treatment called remdesivir, made by US-based Gilead Sciences, is already in the final stages of clinical trials in Asia and doctors in China have reported it has proven effective in fighting the disease. But only randomised trials will allow scientists to know for sure if it really helps or whether patients would have recovered without it.
Heat and light create new biocompatible microparticles Durham NC (SPX) Mar 13, 2020 Biomedical engineers at Duke University have devised a method for making small particles that are safe for living tissues that will allow them to create new shapes attractive for drug delivery, diagnostics and tissue engineering. The results appear online on March 12 in the journal Nature Communications. "With nothing more than some heat and light, we can make some pretty bizarre microparticles," said Stefan Roberts, a biomedical engineering research scientist at Duke. "The technique is simp ... read more
|
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |